Instrument Inactif

Autres langues Taro Pharmaceutical Industries Ltd. Other OTC

Actions

IL0010827181

Produits pharmaceutiques

Cours en clôture Other OTC
- ^USD	-

01/07	La FDA accorde une approbation provisoire pour l'ANDA 212581 concernant la mousse topique d'acide azélaïque	CI
24/06/24	Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) a acquis la participation restante de 21,5 % dans Taro Pharmaceutical Industries Ltd. (NYSE:TARO) auprès de Krensavage Asset Management, LLC et d'autres parties pour un montant d'environ 1,5 million d'euros.	CI

Autres langues

01/07	FDA Grants Tentative Approval for ANDA 212581 Azelaic Acid Topical Foam
08/04	La historia de la semana: ¿Por qué el mercado bursátil israelí resiste tan bien?
25/06/24	Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index
24/06/24	Taro Pharmaceutical Industries : Sun Pharma Completes Taro Merger Form 6 K
24/06/24	Sun Pharmaceutical Industries Limited acquired remaining 21.5% stake in Taro Pharmaceutical Industries Ltd. from Krensavage Asset Management, LLC and others for approximately
23/05/24	Taro Pharmaceutical's Shareholders Approve Merger With Sun Pharmaceutical
23/05/24	Taro Shareholders Approve Merger with Sun Pharma
23/05/24	Taro Shareholders Approve Merger with Sun Pharma
23/05/24	Taro Pharmaceutical Industries : Shareholders Approve Merger with Sun Pharma - Form 6-K
21/05/24	Taro Pharmaceutical Industries : PROVIDES RESULTS FOR YEAR ENDED MARCH 31, 2024 - Form 6-K
20/05/24	Taro: Fiscal Q4 Earnings Snapshot
20/05/24	Taro Pharmaceutical Industries Fiscal Q4 Earnings, Revenue Rise
20/05/24	Earnings Flash (TARO) TARO PHARMACEUTICAL INDUSTRIES Reports Q4 Revenue $164.9M, vs. Street Est of $156.1M
20/05/24	Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Full Year Ended March 31, 2024
20/05/24	Taro Pharmaceutical Industries Ltd. Reports Earnings Results for the Fourth Quarter Ended March 31, 2024
20/05/24	Taro Provides Results for Year Ended March 31, 2024
15/05/24	Taro to Release Full Year Results on May 20, 2024
09/05/24	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote 'FOR' Taro Sun Pharma Merger
08/05/24	Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Taro Shareholders Vote “FOR” Taro Sun Pharma Merger
22/04/24	TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
15/04/24	Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.
07/02/24	TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TARO
30/01/24	Kuehn Law Encourages PGTI, TAST, TARO, and ANSS Investors to Contact Law Firm
30/01/24	Krensavage Asset Management Remains Opposed to Sun's Predatory Bid for Taro
25/01/24	Taro Pharmaceutical Industries Fiscal Q3 Net Income, Net Sales Rise; Shares Climb After Hours